297 related articles for article (PubMed ID: 8822928)
21. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
Broze GJ; Higuchi DA
Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
[TBL] [Abstract][Full Text] [Related]
22. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
23. Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
de Fouw NJ; Haverkate F; Bertina RM
Adv Exp Med Biol; 1990; 281():235-43. PubMed ID: 2102614
[TBL] [Abstract][Full Text] [Related]
24. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
Bajzar L; Morser J; Nesheim M
J Biol Chem; 1996 Jul; 271(28):16603-8. PubMed ID: 8663147
[TBL] [Abstract][Full Text] [Related]
25. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
26. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
27. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
28. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
Urano T
Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
[TBL] [Abstract][Full Text] [Related]
29. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
Toh CH
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
[TBL] [Abstract][Full Text] [Related]
30. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
32. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.
Dai L; Mitchell M; Savidge G; Alhaq A
J Thromb Haemost; 2004 Dec; 2(12):2200-4. PubMed ID: 15613027
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.
Vercauteren E; Emmerechts J; Peeters M; Hoylaerts MF; Declerck PJ; Gils A
Blood; 2011 Apr; 117(17):4615-22. PubMed ID: 21343611
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles.
Hashimoto M; Yamashita T; Oiwa K; Watanabe S; Giddings JC; Yamamoto J
Thromb Haemost; 2002 Jan; 87(1):110-3. PubMed ID: 11848438
[TBL] [Abstract][Full Text] [Related]
35. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Meijers JC
J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
[TBL] [Abstract][Full Text] [Related]
36. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
37. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
Plug T; Marquart JA; Marx PF; Meijers JC
J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
[TBL] [Abstract][Full Text] [Related]
38. Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis.
Mochizuki L; Sano H; Honkura N; Masumoto K; Urano T; Suzuki Y
Thromb Haemost; 2023 Jan; 123(1):16-26. PubMed ID: 36307100
[TBL] [Abstract][Full Text] [Related]
39. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.
Suzuki Y; Sano H; Mochizuki L; Honkura N; Urano T
Blood Adv; 2020 Nov; 4(21):5501-5511. PubMed ID: 33166409
[TBL] [Abstract][Full Text] [Related]
40. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
